Last reviewed 2026-04-19 · How we verify

vitreoscilla filiformis cream

L'Oreal · Phase 1 active Small molecule

vitreoscilla filiformis cream is a Small molecule drug developed by L'Oreal. It is currently in Phase 1 development.

At a glance

Generic name	vitreoscilla filiformis cream
Sponsor	L'Oreal
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Prospective, Randomized, Double Blind Comparative Study on the Use of Two Creams in Xerosis Atopic Probands (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

vitreoscilla filiformis cream CI brief — competitive landscape report
vitreoscilla filiformis cream updates RSS · CI watch RSS
L'Oreal portfolio CI

Frequently asked questions about vitreoscilla filiformis cream

What is vitreoscilla filiformis cream?

vitreoscilla filiformis cream is a Small molecule drug developed by L'Oreal.

Who makes vitreoscilla filiformis cream?

vitreoscilla filiformis cream is developed by L'Oreal (see full L'Oreal pipeline at /company/l-oreal).

What development phase is vitreoscilla filiformis cream in?

vitreoscilla filiformis cream is in Phase 1.

Manufacturer: L'Oreal — full pipeline